Dow Jones
39.387,76 +331,36 (+0,85%) Nasdaq
16.346,26 +43,46 (+0,27%) Nikkei 225
38.073,98 -128,42 (-0,34%) EUR/USD
1,0786 +0,0035 (+0,32%) Bitcoin EUR
58.223,71 +1.310,90 (+2,30%) CMC Crypto 200
1.347,18 +47,08 (+3,62%)
CELU May 2024 10.000 call
| Chiusura precedente | 0,3000 |
| Aperto | 0,3000 |
| Denaro | 0,0000 |
| Lettera | 0,0000 |
| Prezzo d'esercizio | 10,00 |
| Scadenza | 2024-05-17 |
| Min-Max giorno | 0,3000 - 0,3000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 35 |
GlobeNewswireCelularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors
Pharmaceutical and Academic Veteran Brings Significant Innovative Technology and Development Expertise Launching New Cellular TherapiesFLORHAM PARK, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and advanced biomaterial products, today announced the appointment of Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors. Dr. Ling, a distinguished academic and
- GlobeNewswire
Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron
Celularity to provide research support for Regeneron's targeted, allogeneic, chimeric antigen receptor (CAR) T-cell therapyAgreement underscores Celularity's demonstrated expertise in cell therapy research FLORHAM PARK, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing allogeneic cell therapies and biomaterial products, announced today a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals, Inc.
- GlobeNewswire
Celularity Inc. Announces $3 Million Registered Direct Offering
FLORHAM PARK, N.J., July 27, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the purchase and sale of 8,571,428 shares of its Class A common stock together with warrants to purchase up to 8,571,428 shares of its Class A common stock at a combined
